Evidence map›Paper›PMID 39882724›Full record

ReviewCNS spectrums2025

MDMA-assisted therapy: challenges, clinical trials, and the future of MDMA in treating behavioral disorders.

Steve O'Brien, David Nutt

Abstract readReview
In one paragraph

Review in CNS spectrums, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Post-traumatic stress disorder.Nature reviews. Disease primers · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Steve O'BrienDepartment of Brain Sciences, Imperial College London, London, UK.ORCID 0000-0002-9567-9997
David NuttDepartment of Brain Sciences, Imperial College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This chapter explores the complex and controversial path of MDMA-assisted therapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) and other behavioral disorders. It covers MDMA's history from research to recreation to medicine, the pivotal trials, and the challenges faced by researchers. Despite recent setbacks for the clinical application of MDMA, the chapter argues that it holds potential for transforming psychiatry and discusses the uncertain future amidst ongoing debates over ethics, methodology, and political influence.

Indexed as

HallucinogensMental DisordersN-Methyl-3,4-methylenedioxyamphetamineStress Disorders, Post-TraumaticClinical Trials as TopicHumansHallucinogensN-Methyl-3,4-methylenedioxyamphetamineBehavioral disordersdrug regulationFDAMDMA-assisted therapymental healthnovel therapeutic innovationspsychedelic researchpsychotherapyPTSD

Identifiers

PMID39882724
PMCPMC13064729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.